ResVita Bio
PrivateLast Round
Grant
Sep 24, 2024
Total Funding Raised
$2.28M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ResVita Bio is a biotechnology company that develops treatments for skin diseases using synthetic biology. The company's proprietary platform utilizes genetically engineered bacteria, applied topically, to function as living cellular factories that deliver therapeutic proteins directly to the affected skin. This method, which they call "continuous protein therapy," is designed to provide sustained, targeted treatment while minimizing systemic side effects. ResVita Bio is focused on developing therapies for conditions such as Netherton Syndrome, a rare genetic skin disorder, and atopic dermatitis. The company was co-founded by CEO Dr. Amin Zargar and synthetic biology pioneer Dr. Jay Keasling. It has received multiple Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) to advance its research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ResVita Bio Comparables
Compare ResVita Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MatriSys Bioscience | 85% | |
| Azitra, Inc. | 84% | |
| Revance | 77% |
ResVita Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 24, 2024 | ||||
| Seed | Dec 6, 2023 | ||||
| Grant | Sep 18, 2023 | ||||
| Grant | Sep 20, 2022 |
ResVita Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | Grant |
| Pioneer Fund | Seed |
| NIH RADx | Grant |
| Gaingels | Seed |
| Berkeley Frontier Fund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 30% MoM.
- Jul 26, 2026
Monthly visitors increased 90% MoM.
ResVita Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ResVita Bio's valuation, stock price, and market status.
Is ResVita Bio a public or private company?
ResVita Bio is a private company.
What is the current stock price of ResVita Bio?
ResVita Bio is a private company with no public stock price. Caplight tracks ResVita Bio's secondary market activity and provides MarketPrice estimates to Caplight users.
How much is ResVita Bio worth (valuation)?
Valuation information for ResVita Bio is not publicly available.
Can I buy ResVita Bio stock?
ResVita Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ResVita Bio's last funding round?
ResVita Bio's most recent funding round was Grant on September 24, 2024.
Who are the main investors in ResVita Bio?
Key investors in ResVita Bio include National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pioneer Fund, NIH RADx, Gaingels, Berkeley Frontier Fund.
Will ResVita Bio IPO soon?
No public IPO plans have been announced for ResVita Bio.
How can I track ResVita Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ResVita Bio's secondary market activity and sign up for updates.